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Although there is increasing appreciation of the role of the host inflammatory response in 
determining outcome in patients in colorectal cancer, there has been little concerted effort to 
favourably manipulate cancer-associated inflammation, either alone or in combination with current 
oncological treatment. Epidemiological and cardiovascular disease studies have identified aspirin, 
other nonsteroidal anti-inflammatory drugs and statins as potential chemotherapeutic agents which 
may manipulate the host inflammatory response to the benefit of the patient with cancer. Similarly, 
evidence of a chemotherapeutic effect of histamine-2 receptor antagonists, again mediated by an 
immunomodulatory effect, has previously led to increased interest in their use in gastrointestinal 
cancer. Extensive pre-clinical data and a limited number of clinical investigations have proposed a 
direct effect of these agents on tumour biology, with an anti-tumour effect on several of the 
hallmarks of cancer, including proliferative capacity, evasion from apoptosis and cell cycle regulation, 
and invasive capability of tumour cells. Furthermore, clinical evidence has suggested a pertinent role 
in down-regulating the systemic inflammatory response whilst favourably influencing the local 
inflammatory response within the tumour microenvironment. Despite such compelling results, the 
clinical applicability of nonsteroidal anti-inflammatory drugs, statins and histamine-2 receptor 
antagonists has not been fully realised, particularly in patients identified at high risk on the basis of 
inflammatory parameters. In the present review, we examine the potential role that these agents 
may play in improving survival and reducing recurrence in patients with potentially curative colorectal 
cancer, and in particular focus on their effects on the local and systemic inflammatory response. 
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Introduction 
Colorectal cancer (CRC) is the second most common cause of cancer-related death in Western Europe 
and North America. In the UK, 41 000 new cases are diagnosed each year with over 16 000 deaths(1). 
Despite advances in surgical and adjuvant treatment over the past two decades, survival remains 
poor, with a five-year survival of approximately 50% in patients undergoing resection with curative 
intent(2). Since the establishment of 5-fluorouracil and platinum-based regimes, few new 
chemotherapeutic agents have shown any significant survival benefit(3). Similarly, biological agents, 
such as bevacizumab and cetuximab have proven to be of only modest benefit, and only in the 
palliation of metastatic disease(4). As such, there remains a need to identify potential adjuvant and 
neo-adjuvant agents in patients with CRC.  
Inflammation has been implicated in the pathogenesis of many adult malignancies and is now 
recognised as the seventh “hallmark” of cancer(5). Furthermore, the host inflammatory response to 
CRC influences disease recurrence and survival. A pronounced local inflammatory response with intra- 
and peri-tumoural lymphocytic infiltration is a stage-independent predictor of increased survival(6). 
Conversely, up-regulation of the systemic inflammatory response has been shown to be a predictor of 
recurrence and reduced survival in several cancers including CRC (7).  
Impaired cell-mediated immunity is common in cancer patients(8). Particularly in patients undergoing 
surgical resection of CRC, that is recognised to attenuate post-operative cell-mediated immunity(9), 
this may be an important mechanism by which disseminated or shed tumour cells evade effective 
immunosurveillance and establish de novo metastases(10-12). Furthermore, the presence of a 
systemic inflammatory response has been associated with a poorer response to chemotherapeutic 
agents and an increased risk of toxicity(13). 
It is clear that manipulation of the host inflammatory response, particularly in those patients with an 
“unfavourable” inflammatory profile, presents an intriguing concept. Despite this, few agents have 
been examined in the clinical setting for their potential effects on CRC-associated inflammation, 
particularly in the context of contemporary surgical and oncological treatment of high-risk disease. 
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), including the cyclooxygenase-2 
inhibitors (COXIBs), have been identified as potential chemotherapeutic drugs which may favourably 
manipulate the inflammatory response in CRC. Despite convincing evidence from epidemiological 
studies and cardiovascular secondary prevention trials of a chemoprophylactic effect in reducing CRC 
incidence and mortality(14, 15), it is relatively recently that a potential benefit in patients with 
established CRC has been realised, with NSAID users less likely to present with advanced or 
metastatic disease at diagnosis or follow-up(16, 17). Indeed, emerging evidence of as much as a 40% 
reduction in mortality in patients undergoing curative treatment makes the concept of the use of 
   
5  
NSAIDs as adjuvant treatment in high risk disease more compelling(13, 18-23), where potential 
survival benefits may outweigh the risks which have so far abrogated their use in CRC prevention(24).  
Similarly, statins and histamine-2 receptor antagonists (H2RAs) have also been identified as drugs 
with a potential benefit in improving survival and reducing risk of recurrence in patients with 
established CRC. A direct effect on tumour biology has been proposed through manipulation of 
several key signalling pathways, with a resultant effect on several of the key hallmarks of 
carcinogenesis, including proliferative and anti-apoptotic capacity as well tumour-mediated 
angiogenesis and invasiveness (25). Furthermore, these drugs have also been identified as potential 
agents capable of manipulating the host systemic and local inflammatory response to CRC[Table 1]. 
Although the use of such agents to manipulate the tumoural and inflammatory microenvironment in 
CRC as well as the systemic inflammatory response presents an attractive concept, most evidence to 
date arises from in vitro and in vivo investigations, with little confirmation from clinical studies. In 
particular, there has been no attempt to stratify the use of anti-inflammatory agents and subsequent 
benefit in CRC patients according to the presence of a systemic inflammatory response.The present 
review examines the clinical evidence supporting the use of NSAIDs, statins and H2RAs in influencing 
the tumour microenvironment and host inflammatory response in CRC and focuses on their utility in 
improving survival in patients with potentially curative disease. 
 Aspirin, NSAIDs and COX-2 inhibitors 
Early evidence of a prophylactic effect of aspirin and NSAIDs in CRC originally arose out of studies of 
hereditary cancer syndromes. The use of NSAIDs decreases the number and size of colonic polyps in 
patients with familial adenomatous polyposis; similarly, aspirin has also been found to confer a 
protective effect on the colorectum in patients with Lynch syndrome(26, 27). Over the past two 
decades, increasing evidence from epidemiological studies has identified a potential role in the 
prophylaxis of sporadic CRC, with an approximate 30% risk reduction with aspirin and non-aspirin 
NSAIDS and a potentially greater reduction with COXIB use(28, 29). In general, a duration-dependent 
increase in risk reduction has been observed, with the greatest benefit seen after at least 10 years of 
continuous use. Similarly, cessation of regular use results in a return to normal population risk for 
subsequent CRC development. Furthermore, secondary analyses of cardiovascular secondary 
prevention trials have found a significant benefit with aspirin doses commonly employed for 
cardiovascular disease prevention, rather than doses commonly associated with analgesic use (19). 
Despite such convincing evidence, concerns regarding the safety profile of NSAIDs have discouraged 
their use as prophylactic agents in the general population, at least until the optimal target population 
is identified(24).  
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Direct Tumoural Effects 
The direct cellular effects of aspirin and other NSAIDs have been under close scrutiny since their anti-
tumour effects were first appreciated, and have been reviewed extensively elsewhere. In general, 
pre-clinical investigations have found an increase in tumour cell apoptosis in association with a 
decrease in cell proliferation, angiogenesis and metastatic potential(30, 31). Although limited, 
mechanistic studies in patients with CRC have again suggested similar effects, with an NSAID-
mediated decrease in primary and metastatic tumour blood flow and microvessel density even with 
short courses of NSAIDs(32, 33). Of further interest, NSAID administration has also been shown to 
facilitate tumour cell differentiation, with a loss of cancer cell stemness and down-regulation of gene 
expression associated with increased metabolic turnover and resistance to oxidative stress(34, 35). 
 Cyclooxygenase-dependent effects 
Several potential mechanistic pathways have been implicated in the anti-tumour effects of aspirin 
and other NSAIDs. The most studied mechanism is their inhibitory effect on cyclooxygenase (COX)-
mediated synthesis of prostanoids, and in particular prostaglandin E2 (PGE2)(30, 31, 36, 37). Increased 
synthesis of PGE2 by COX-2, the inducible form of the enzyme has been shown to have several pro-
tumour and immunosuppressant effects in vitro and in vivo, including an increase in tumour cell 
proliferation, decreased apoptosis, increased angiogenesis and increased chemo- and radio-
resistance. Indeed, COX-2 is overexpressed in some but not all colorectal neoplasia, particularly those 
arising in the distal colon and rectum (38, 39), where its expression is associated with increased 
differentiation, tumour invasiveness, metastatic potential and poorer survival(30, 36, 40). 
Furthermore, epidemiological evidence suggests a prominent role for COX-2 inhibition, with a 
reduced risk of COX-2 overexpressing tumours in long-term aspirin users and a modification of their 
anti-tumour effects observed in patients with common COX-2 gene polymorphisms(41, 42). Similarly, 
an increase in tumour cell apoptosis and decrease in tumour vascularity has also been confirmed in 
human subjects in response to NSAID administration, mediated by a reduction in COX-2 expression 
and tissue PGE2(32, 43). 
Aspirin, particularly at low doses employed in cardiovascular disease, is a weak inhibitor of COX-2 
whereas it remains a strong inhibitor of the constitutive enzyme COX-1, particularly in anucleated 
cells such as platelets(44). As such, inhibition of COX-1 has also been suggested as another potential 
mechanism for the anti-tumour effects of NSAIDs by inhibiting platelet activation, facilitating 
immunosurveillance and preventing haematogenous spread. Indeed, aspirin can abrogate the 
increase in platelet activation demonstrated in CRC patients, even after only five days (45).  
Cyclooxygenase-independent effects 
Although many of the anti-proliferative effects of NSAIDs may be explained by their inhibitory effects 
on PGE2 synthesis, several COX-independent actions have also been identified (46). Similarly, many of 
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the effects of NSAIDs on proliferation and apoptosis have also been identified in cancer cell lines 
known not to express COX-2 (47). Several signal transduction pathways, including Wnt/β-catenin, 
nuclear factor-kappa B (NF-ĸB) and the phosphatidylinositide 3-kinase/AKT/mammalian target of 
rapamycin pathway have been identified as potential targets for the non-COX mediated effects of 
NSAIDs, with limited clinical evidence suggesting an NSAID-mediated effect on associated signalling 
and transcription pathways(47-49). Furthermore, epidemiological data again suggests these as valid 
targets of NSAID therapy in CRC, with increased survival with aspirin use in patients with PIK3CA 
mutated cancers(49), and a reduced risk of cancer with NSAIDs in patients with mutations within the 
NF-ĸB pathway(50).   
Effects on cancer-related inflammation 
The anti-inflammatory properties of aspirin and non-aspirin NSAIDs have identified them as likely 
candidates in the manipulation of CRC-related inflammation; indeed evidence of a NSAID-mediated 
attenuation of the acute phase response and weight loss in advanced cancer suggests a potential role 
in the management of the cancer cachexia syndrome(51). Furthermore, the chemoprophylactic 
effects of NSAIDs appear to be greater in patients with evidence of a systemic inflammatory 
response(52), although unfortunately, so do the cardiovascular risks of long-term COXIB use(53). 
 Local inflammation 
The presence of a pronounced inflammatory infiltrate at the invasive margin and within the tumour 
stroma is recognised as an indicator of reduced recurrence and superior survival(6). The effects of 
aspirin, non-selective NSAIDs and COXIBs on the tumoural inflammatory response have been 
investigated in a number of solid cancers, with significant anti-tumour responses identified in 
gastrointestinal, breast, bladder and head and neck cancers(54). A decrease in the levels of pro-
tumour, immune-suppressing cytokines including PGE2, has been identified in the colorectum and in 
colorectal hepatic metastases, likely mediated at a gene transcription level.(32, 34, 43). Furthermore, 
NSAIDs have been shown to induce expression of MHC class II molecules on the surface of CRC 
cells(55). Such changes within the tumour milieu may in turn allow for the recruitment and 
propagation of a co-ordinated, effective anti-tumour lymphocytic response [Table 2]. Indeed, 
Lönnroth and colleagues have shown an increase in tumour infiltration of activated T-lymphocytes 
and a decrease in immunosuppressive regulatory T-lymphocytes (Treg) following a short course of pre-
operative indomethacin or celecoxib in patients with CRC(55). Similarly, indomethacin augmented the 
anti-carcinoembryonic antigen (CEA) immune response in CRC patients ex vivo through inhibition of 
COX-2 and Treg activity(56). The authors concluded that COX-2 inhibition could attenuate the 
inhibitory activity of Treg cells identified in tumour tissue and regional lymph nodes, promoting an 
effective anti-tumour inflammatory response. The oncological benefits of NSAID-mediated 
manipulation of the local inflammatory response remain to be elicited. 





Suppression of the innate and adaptive immune response has been identified in patients with CRC(57, 
58), with further attenuation of systemic immunity identified following exposure to surgical stress(59, 
60). Indeed, cancer-related immune suppression is thought to contribute to the risk of recurrence 
through failure of immunosurveillance and the ability to clear micrometastatic deposits, residual 
microscopic disease and tumour cells shed at the time of surgery(10, 11). The administration of 
NSAIDs has been shown to abrogate suppression of systemic lymphocyte and natural killer (NK) cell 
activity in patients undergoing major surgery(59, 60) and in patients with CRC(57, 58) [Table 3]. 
Nonsteroidal anti-inflammatory drugs attenuate the acute phase response in patients with advanced 
cancer, with a decrease in several serum markers of inflammation including C-reactive protein (CRP), 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) identified in tandem with an 
improvement in weight and functional status(51). Furthermore, the effect of NSAIDs on reducing risk 
of CRC appears to be greatest in patients with evidence of systemic inflammation as measured by 
soluble TNF receptor-2 (sTNFR-2) but not CRP(52). Interestingly however, in a polyp prevention study 
utilising low dose aspirin with or without folic acid, aspirin 325mg daily did not decrease CRP but did 
stabilise it over a three year period whereas patients receiving placebo experienced a significant 
increase(61). Regardless, CRP did not predict the chemoprophylactic effects of aspirin use. Despite 
this, the role of NSAIDs in patients with CRC-related systemic inflammation undergoing potentially 
curative surgical resection remains largely unknown [Table 3]. In patients with rectal cancer, the use 
of celecoxib has been shown to decrease elevated circulating levels of TNFα and IL-8, potentially 
through a direct effect on tumour cells and NFĸB activity(62). Similarly, in CRC patients with an 
elevated CRP, ibuprofen decreases circulating CRP, cortisol and IL-6(63). Whether attenuation of the 
systemic inflammatory response by NSAIDs in CRC patients undergoing curative surgery translates 
into a benefit in recurrence rates and survival however remains unknown, and must be addressed by 
future trials of neoadjuvant and adjuvant NSAID use.  
Disease progression and survival 
Recent evidence has suggested a potential beneficial effect of NSAIDs on CRC progression, with as 
much as a 40% reduction in CRC-specific mortality with regular aspirin and NSAID use(19-23). 
Rothwell and co-workers suggested that the observed reduction in mortality apparent on secondary 
analysis of cardiovascular disease prevention trials was greater than what would be expected as a 
result of an NSAID-mediated decrease in cancer incidence alone(19). In addition, evidence that NSAID 
users are less likely to present with advanced or metastatic disease at diagnosis or follow-up further 
supports a direct effect on disease progression(16, 17). 
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Given such compelling evidence of an NSAID-mediated effect on established CRC, it is not surprising 
that their potential utility as adjuvant agents is currently being considered(13). Certainly, analysis of 
pre- and post-diagnosis NSAID usage further confirms a potential role for aspirin in addition to 
potentially curative surgery and adjuvant therapy,  with an almost 50% reduction in cancer mortality 
in patients who commence regular aspirin use following diagnosis(64). Interestingly, no significant 
survival benefit was seen in patients continuing pre-diagnosis aspirin use, suggesting that cancers 
arising in these circumstances may be aspirin-resistant (64, 65).  
Surprisingly, there have been few trials of aspirin or NSAIDs as adjuvant agents in CRC. Sub-analysis of 
a randomised trial of 5-fluorouracil and leucovorin with or without irinotecan in patients with stage III 
colon cancer examined the effect of aspirin and COXIBs on recurrence and survival(66). Even after 
controlling for treatment arm, NSAID use was associated with a 50% reduction in disease recurrence 
or death. Two further clinical trials of adjuvant COXIB following curative resection in patients with 
stage II/III disease ceased recruitment early following concerns regarding the cardiovascular safety 
profile of prolonged COXIBs(67, 68). The VICTOR trial, which randomised patients who had undergone 
surgery and adjuvant treatment for stage II/III disease to daily rofecoxib or placebo, was terminated 
early with only 33% of patients receiving active treatment for at least one year(67). Interestingly 
however, despite no significant difference in cancer-specific mortality and recurrence-free survival, a 
statistically significant reduction in recurrence within the first year was found with regular COXIB use. 
Given that most adenoma prevention trials exposed patients to at least two years of regular COXIB 
use, the early termination of VICTOR likely precluded the investigators from finding any significant 
survival benefit. 
Given the observed effects on tumour biology and micro-environment, the use of NSAIDs prior to 
surgery in addition to standard neoadjuvant chemoradiotherapy has also been investigated. Indeed, 
decreased synthesis of protective prostaglandins via inhibition of COX-2 has been shown to increase 
tumour radiosensitivity(69). To date however, only phase II feasibility studies have shown a potential 
increase in tumour response and clinicopathological downstaging with the addition of COXIBs to 
neoadjuvant chemoradiotherapy(70). Certainly such time-restricted use may be promising and favour 
the risk-benefit ratio of COXIB use. Regardless, although trials of adjuvant aspirin use are currently 
recruiting(4), it is clear that further, adequately powered trials are required to fully ascertain the 
benefit of aspirin, NSAIDs and COXIBS, both in the adjuvant and neoadjuvant setting. 
Statins 
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as 
statins, are primarily used in the treatment of hypercholesterolaemia and atherosclerotic 
cardiovascular disease and are known to have a number of pleiotropic effects on cell proliferation, 
angiogenesis, inflammation and endothelial cell function(71, 72). Although a reduction in the risk of 
several cancers has been found in epidemiological studies(73-75), the results of meta-analyses 
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suggest only a modest effect if any of statins on reducing the incidence of CRC in the general 
population(72, 76). Despite this, the results of in vivo studies and evidence of an increased expression 
of HMG-CoA reductase in colon cancer, particularly tumours arising in the left colon, suggests a 
potential role for statins in the treatment of CRC(77). 
Direct tumoural effects 
Mevalonate, the end product of HMG-CoA reductase metabolism and its isoprenoid metabolites are 
required for the activation of the Ras superfamily of small GTPases by prenylation(78). In turn, these 
GTPases are crucial for downstream activity of several signal transduction pathways(79); inhibition of 
mevalonate synthesis by statins subsequently has indirect and direct effects on cell survival and 
growth. Such inhibition has been shown to have a pleiotropy of effects, including a reduction in cell 
proliferation(77, 80), induction of apoptosis(77, 80), increased susceptibility to oxidative stress(81) 
and inhibition of metastatic transformation and angiogenesis(82). A role for non HMG-CoA reductase-
mediated pathways has also been suggested, particularly in tumours exhibiting the CpG island 
methylator phenotype (CIMP). CIMP-associated tumours exhibit hypermethylation of tumour 
suppressor gene promoter regions, including those implicated in the bone morphogenic protein 
(BMP) pathway(83). Statin-mediated demethylation of the BMP2 promoter region and subsequent 
activation of the BMP pathway has previously been shown to increase apoptosis and promote cell 
differentiation in cell line studies(84); indeed such an effect may suggest a pertinent role for statins in 
patients with CIMP-associated tumours. 
Of further interest, statin therapy has been shown to augment the activity of a number of 
chemotherapeutic agents, even in resistant cell lines(78, 85, 86). The activity of epidermal growth 
factor receptor inhibitors, including cetuximab, also appears to be potentiated in vitro and in vivo, 
even in cell lines with known KRAS mutations and resistance(87). Furthermore, statin therapy may 
also increase the likelihood of pathological complete response following neoadjuvant 
chemoradiotherapy(85, 88). 
Effects on cancer-related inflammation 
Cardiovascular disease prevention trials have identified a clear anti-inflammatory effect of statins, 
with down-regulation of pro-inflammatory cytokines and increased cardiovascular risk reduction in 
patients with elevated serum inflammatory markers(89). Furthermore, favourable effects on organ 
rejection following heart and renal transplant suggest a potent immunomodulatory effect, potentially 
through a direct effect on MHC class II expression and subsequent T-cell activation(90). Similar effects 
on the inflammatory response may also be expected in patients with CRC, and certainly evidence 
from clinical trials of a 90% reduction in risk of inflammatory bowel disease-related CRC is 
compelling(91). 
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Local inflammation 
To date, no clinical evidence exists to support the role of statins in influencing the local inflammatory 
response in CRC, although pre-clinical data suggests a direct inhibitory effect on NF-ƙB activation, with 
subsequent down-regulation of COX-2 and pro-inflammatory cytokine expression(92-94). A cohort 
study of patients undergoing radical prostatectomy found that statin use was associated with a 
reduced tumour inflammatory infiltrate(95); in contrast to CRC, however, a minimal local 
inflammatory response is associated with reduced recurrence and improved survival. Whether similar 
effects on the tumour inflammatory infiltrate in CRC can be expected remains to be seen.  
 Systemic inflammation 
Despite a clear benefit on the systemic inflammatory response in cardiovascular disease and in 
patients following transplant, the clinical application of these effects in CRC is less clear [Table 3]. In 
an interventional study of patients undergoing curative CRC resection, Malicki and co-workers found a 
significant reduction in pre-operative serum IL-6 in patients receiving statins(96). In contrast however, 
a recent study of the systemic inflammatory response to neoadjuvant chemoradiotherapy in patients 
with oesophageal and rectal cancer found that concomitant statin use did not attenuate the serum 
inflammatory response or treatment-associated symptoms(97). Further clarification of the effects of 
statins on cancer-related systemic inflammation is required, and such measures should be 
incorporated in to future studies of the chemotherapeutic benefits of statins. 
Disease progression and survival 
Despite an unclear effect on the incidence of CRC, statins may influence the progression of 
established disease, with regular statin use being associated with earlier stage at diagnosis in three 
case-control studies(73, 98, 99). Siddiqui and co-workers, in a case-control study of 326 male users 
with CRC and regular statin use of at least three years, found a lower mean stage and lower frequency 
of metastases (28.4% vs. 38.8%, p<0.01) at presentation, with a higher prevalence of right-sided 
tumours in statin users(99). Furthermore, statin users had superior five-year survival (37% vs. 33%, 
p=0.03). Coogan and colleagues also found a significant reduction in the risk of stage IV CRC (odds 
ratio 0.18, 95% CI 0.05-0.62) with regular use of statins for at least 3 months(98).  Similarly, a modest 
reduction of stage III/IV CRC was also observed by Poynter et al, however this failed to reach 
statistical significance (odds ratio 0.90, 95% CI 0.54 to 1.50). In contrast however, despite finding a 
reduced risk of CRC with statin use, a recent case-control study with prescription data linkage from 
Scotland found no difference in stage at diagnosis or survival(75), although the study was 
underpowered to identify any significant survival benefit. Of more interest, a prospective 
observational study of statin use within a randomised trial of adjuvant chemotherapy in stage III colon 
cancer found no survival benefit with statin use, irrespective of duration of use or presence of KRAS 
mutations(100). These conflicting results may in part be explained by population-based genetic 
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variation in HMG-CoA reductase, as the presence of single nucleotide polymorphisms have previously 
been shown to modify the protective effect of statins on risk of CRC(101). 
It is clear that the benefit of statins in the treatment of CRC has not yet been defined and that further 
clinical trials are required. Recruitment for the National Surgical Adjuvant Breast and Bowel Project: 
Statin Polyp Prevention Trial is currently underway with the aim of investigating the effects of 
rosuvastatin on polyp/cancer recurrence and metachronous cancer development in patients who 
have undergone resection for stage I/II colon cancer(102). This and further trials may in time define 
the role statins may play in treatment of CRC. 
H2RAs 
Since early reports of a survival advantage in patients with gastric cancer(103), there has been 
interest in the potential use of H2RAs in the treatment of CRC. Aside from potentially beneficial 
effects on the local and immune responses, pre-clinical data suggests direct anti-tumour effects, 
including inhibition of histamine as a growth factor and inhibition of tumour-endothelial cell adhesion 
and motility. Furthermore, prolonged H2RA use has been shown to increase the systemic 
bioavailability of 5-fluourouracil(104).  
Direct tumoural effects 
Histamine acts as an autocrine tumour growth factor and has been shown to increase CRC cell 
proliferation and growth in vitro and in vivo(105). Indeed, expression of histamine and histidine 
decarboxylase, the enzyme responsible for histamine synthesis, is increased in CRC when compared 
to normal colorectal mucosa(106, 107); increasing expression has been associated with the presence 
of nodal and distant metastases as well as increased microvessel density, suggesting a potential role 
in the transformation to invasive and metastatic disease. Furthermore, histamine has also been 
shown to increase expression of COX-2 and PGE2 as well as vascular endothelial growth factor in cell 
lines constitutively expressing COX-2(106). Celecoxib has been shown to abrogate the histamine-
induced increase in vascular endothelial growth factor expression, suggesting that at least some of 
the pro-tumour effects of histamine may be mediated by COX-2 and prostaglandin activity(106). 
Although several histamine receptors have been identified with H2 and H4 receptor stimulation both 
being implicated in tumour growth(106), only H2 receptors appear to be preserved in CRC tissue with 
loss of H1 and H4 receptors when compared to normal mucosa(108). The use of H2RAs in both cell 
line and animal studies has been associated with a decrease in histamine-induced tumour growth, 
proliferation and increase in apoptosis in vitro(105, 109). The use of H2RAs may also reduce the 
metastatic potential of colorectal tumour cells by inhibition of E-selectin expression, endothelial cell 
adhesion and a decrease in tumour microvessel density(106, 110).  
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Effects on cancer-related inflammation 
Local inflammation 
Activation of histamine receptor-2 on regulatory T-lymphocytes inhibits the cell-mediated immune 
response(111). Amelioration of this immunosuppressant effect by H2RA use has been shown to 
subsequently increase tumour infiltration of activated lymphocytes [Table 2]. Adams and co-workers, 
using quantitative assessments of peri-tumoural lymphocytic infiltration such as the presence of a 
Crohn’s-like reaction or Jass criteria, found an increased conspicuous lymphocytic infiltration with 
peri-operative cimetidine use(112, 113). Qualitative assessment of the lymphocytic infiltrate using 
immunohistochemistry have been equivocal, with one study suggesting that H2RA use increases 
tumour infiltration of CD3+ T-lymphocytes, particularly in patients with late stage disease(9), whereas 
another study examining the dose-response of cimetidine suggested that H2RAs may exert their 
effects through other, non-CD3+ cellular components(114). Interestingly, Kapoor et al. found that pre-
operative use of the H2RA famotidine led to a significant increase in tumour lymphocyte infiltration in 
colon cancer rather than rectal cancer, with the largest effect seen in those patients with a normal 
pre-operative CEA(115). 
 Systemic inflammation 
Histamine attenuates the systemic immune response in patients with CRC. Similarly, the exaggerated 
post-operative immune suppression experienced in patients with CRC is in part mediated by 
histamine release(9). The use of H2RAs has been shown to abrogate tumour-associated systemic 
immune suppression [Table 3], with restoration of circulating levels and activity of T-lymphocyte and 
NK cell subsets(116), potentially via augmentation of IL-2 and interferon activity. Furthermore, peri-
operative H2RA use restores normal cell-mediated immunity following surgery(9, 117).  Although 
shown to decrease post-operative CRP in patients without cancer (118), the effects of H2RA use on 
systemic cytokine profiles and biomarkers of the systemic inflammatory response in patients with CRC 
remains unknown. 
Survival 
The first reports of a survival advantage for H2RAs in patients with CRC were in the early 1990s, when 
Adams and co-workers reported a non-significant increase in 3-year survival with peri-operative 
cimetidine in patients with Dukes A to C CRC (3-year survival 93% vs. 59%, p=0.17)(112). In 1995, 
Matsumoto and co-workers reported the survival analysis of a multicentre, randomised controlled 
trial of the effects of cimetidine on adjuvant 5-fluorouracil-induced appetite loss and 
oesophagitis(119). Interestingly, they found a significant increase in survival for both colonic and 
rectal cancers at almost 4 years. A 10-year analysis from the same patient cohort further confirmed 
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increased survival and reduced risk of recurrence with cimetidine, with greatest benefit seen in Dukes 
C patients(110).  
Further studies of differing doses and types of H2RAs given either prior to surgery or as adjuvant 
treatment have only shown a non-significant trend towards improved survival(114, 115, 120, 121), 
particularly in patients with Dukes C cancers(120). Subgroup analyses have identified potential patient 
groups who may be more likely to benefit from H2RA treatment, such as those with microsatellite 
instability (MSI) low tumours or tumours with a low peritumoural lymphocytic infiltrate(114). MSI-low 
tumours are less likely to have a pronounced lymphocytic infiltrate(122). As such patients with MSI-
low tumours may represent a subgroup of CRC patients likely to benefit from H2RA use, however no 
large scale studies have examined these relationships and therefore this area merits further 
investigation. In addition, patients who did not receive peri-operative blood transfusion or develop 
post-operative infectious complications have similarly been identified as groups who may benefit 
oncologically(121). Differences in type and dose of drug used as well as inclusion of patients with 
metastatic disease at enrolment may have precluded finding significant results in these studies. The 
consistency of trend towards improved survival however does suggest that further, standardised 
studies are required. A recent Cochrane Collaboration review of H2RAs as adjuvant treatment for 
resected CRC found overall a significant improvement in survival for cimetidine only (combined 
hazard ratio (HR) 0.53; 95% confidence interval (CI) 0.32 to 0.87)(123). Given that most of the 
included trials were performed before the routine use of diagnostic cross-sectional imaging, total 
mesenteric excision surgery and contemporary chemoradiotherapy regimes, the authors advised 
caution regarding the applicability of these trials and advised the need for further studies 
incorporating current “best practice” treatment.  
Conclusion 
Increasing appreciation of the role of host-tumour factors has allowed for better identification and 
prognostication of patients deemed at high risk, regardless of pathological staging. Indeed, 
assessment of the local and systemic inflammatory responses should be incorporated in to the 
routine staging of patients with CRC(7, 124).  
Even though measurement of the host inflammatory response allows for greater risk stratification, 
the appropriate management of such patients remains unknown. Although more intense surveillance 
may be beneficial, oncological management is impaired by the systemic inflammatory response(13). 
Certainly it is clear that optimal management should attempt to manipulate the inflammatory 
response. 
In spite of convincing epidemiological evidence, the role of statins, H2RAs and particularly NSAIDs in 
the management of patients with CRC has yet to be defined. Although shown to have a direct effect 
not only on tumour biology but also on the host systemic and local inflammatory response, most 
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evidence has arisen from pre-clinical investigations of CRC in vitro and in vivo. The few clinical 
investigations reviewed above have been limited in their clinical applicability, and the long-term 
oncological outcomes have not yet been fully explored.  
The use of these agents is an attractive option not only because of their low cost, but also due to their 
relatively well-defined long-term safety profiles. Clinical trials of adjuvant aspirin and statins in CRC 
are currently recruiting. It is clear however, that further studies are required to identify the role of 
anti-inflammatory agents in the management of patients with CRC, and particularly those patients 
identified at high risk due to the presence of an “unfavourable” inflammatory profile.  
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